Isotopia Molecular Imaging and Alpha-9 Theranostics Announce Lutetium-177 Supply Agreement

BOSTON, Mass. and VANCOUVER, British Columbia, May 23, 2022 – Isotopia Molecular Imaging and Alpha-9 Theranostics, are pleased to announce the signing of a global clinical supply agreement that provides Alpha-9 with Isotopia’s medical radioisotope no-carrier-added lutetium-177 for the preclinical and clinical development of Alpha-9’s radiopharmaceutical pipeline.

“We are pleased to contribute to Alpha-9’s exciting program,” comments Director of BD Keren Moshkoviz. “Using our  well established experience in radioisotope global production and supply, we aim to further support the development of Targeted Radionuclide Therapies to improve clinical outcomes for patients worldwide.”

Alpha-9 is excited to partner with Isotopia and is committed to developing its pipeline of radiopharmaceuticals for the benefit of patients.